ArticleScientific reports2025
An experimental study of levamisole incorporated diet on fish health and resistance against Pseudomonas aeruginosa isolated from Oreochromas niloticus.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Barbados aloe as a water-administered therapeutic against Pseudomonas aeruginosa infection in Clarias gariepinus: Effects on hemato-biochemical profiles, electrolyte homeostasis, antioxidant capacity, and tissue histology.Veterinary research communications · 2026Article
- Article
- Article
- Temporal microbiome dynamics and fish health-associated dysbiosis in freshwater aquarium systems: a case study from River Wonders Singapore.Frontiers in microbiology · 2026Article
- Levamisole as a Strategy Against Bacteria from Canine Otitis Externa: An In Vitro Evaluation.Veterinary sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudomonas aeruginosa (P. aeruginosa) is one of the most common ones that harm fish. P. aeruginosa has been regarded as one of the most significant threats to the fishing industry, which also affects public health. Thus, the present investigation was done in two steps; the first step was to examine the prevalence and the antibiogram of P. aeruginosa among Nile tilapia (Oreochromas niloticus (O. niloticus)) from aquaculture farms in Kafr El-shiekh Governorate with an emphasis on their antibiotic resistance genes (BlaTEM, tetA, and sul1). The second step was to investigate the effect of levamisole as a feed supplement for tilapia fish on growth performance, immunity, serum biochemistry, and the protective effect against artificial infection with the previously isolated in the first step P. aeruginosa strain. One hundred samples were collected from morbid Nile tilapia fish in the first step. The incidence of P. aeruginosa was 14%. Susceptibility of P. aeruginosa isolates to 9 antimicrobial agents showed that about half of P. aeruginosa isolates were multidrug-resistant (MDR) to (5-6) antibiotics. All of the isolates were sensitive to amikacin, ciprofloxacin, and norfloxacin (100%), and half of them were resistant to azithromycin, amoxicillin with clavulanic, tetracycline, and sulfa with trimethoprim. P. aeruginosa isolates were confirmed diagnosed using the 16S rRNA gene, which was detected in 100% of the tested isolates, and was also evaluated for the presence of antibiotic resistance genes (blaTEM, tetA, and sul1), which were 85.7%, 85.7%, and 100%, respectively. In the second step, a 2-month feeding trial was performed on 160 O. niloticus fish with a weight of 56.75 ± 3 g. Fish were randomly distributed into four groups, each at a rate of 10 fish per aquarium in four replicates, and fed on a diet containing 0.0, 500, 750, and 1000 mg levamisole/kg diet. At the end of the feeding trial, fish were challenged by pathogenic P. aeruginosa, which was isolated in the first step. The results of the in vivo trial showed that levamisole safely improved the growth and immunity of Nile tilapia without side effects on liver function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.